Loading
institutionsInstitution
Instituto Alexander Fleming
The Instituto Alexander Fleming in Buenos Aires, founded in 1994, is Argentina's most research-active cancer centre; it has enrolled Argentine patients in the pivotal HER2, CDK4/6, lung and colorectal trials of the last three decades and hosts the GAICO cooperative group.
Also called: IAFFleming
Overview
The Instituto Alexander Fleming was founded in Buenos Aires in 1994 as a dedicated cancer institute by a group of oncologists including Reinaldo Chacón, and has become Argentina's most research-active cancer centre, with medical, surgical and radiation oncology, haematology, nuclear medicine and a large clinical research department that has enrolled Argentine patients in pivotal breast (HER2, CDK4/6), lung and colorectal cancer trials of the last three decades. It hosts the Grupo Argentino de Investigación Clínica en Oncología (GAICO) and links with the Latin American Cooperative Oncology Group, offers a fellowship programme and tumour banking, and was an early adopter in Argentina of precision oncology and next-generation sequencing.
Location
Buenos Aires, AR
Type
cancer center
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#231 · 26 points (0 Newsweek + 0 NCI + 26 from 13 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-15.
Matched to Instituto Alexander Fleming, including child institutions. 95 works · 547 citations · 74% open access · 9% clinical trials · 1% reviews.
Oncology works per year
162022
262023
172024
222025
142026
Most works
- Juan Manuel O’Connor18 works
- Diego Enrico16 works
- Federico Waisberg16 works
- Matías Chacón12 works
- Federico Esteso10 works
- Berenice Freile9 works
- Romina Luca9 works
- Claudio Martín8 works
- Laura Korin8 works
- Luisina Bruno7 works
Most cited
- International clinical trials
- Breast and lung oncology
- Cooperative group (GAICO)
- Precision oncology
Similar pages
- PersonYeon Hee Park
Shares CDK4/6, Palbociclib, HER2, HER2-positive breast cancer.
- PersonDennis J. Slamon
Shares CDK4/6, Palbociclib, Trastuzumab, HER2.
- PersonAngela DeMichele
Shares CDK4/6, Palbociclib, HR-positive / HER2-negative breast cancer.
- TrialPATINA
Shares Palbociclib, Trastuzumab, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- InstitutionHospital del Mar / Hospital del Mar Research Institute
Shares Trastuzumab, HER2, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- PersonMassimo Cristofanilli
Shares CDK4/6, Palbociclib, HR-positive / HER2-negative breast cancer.
- PersonHelena Earl
Shares Trastuzumab, HER2, HER2-positive breast cancer.
- PersonDebu Tripathy
Shares CDK4/6, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
cancers
fronts
technologies
targets
drugs
ApprovedSmall-molecule CDK4/6 inhibitor
Palbociclib · Ibrance
ApprovedMonoclonal antibody (anti-HER2)
Trastuzumab · Herceptin (and biosimilars, Phesgo with pertuzumab)